✦ LIBER ✦

Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study

✍ Scribed by Hoppe, Bradford S.; Flampouri, Stella; Zaiden, Robert; Slayton, William; Sandler, Eric; Ozdemir, Savas; Dang, Nam H.; Lynch, James W.; Li, Zuofeng; Morris, Christopher G.; Mendenhall, Nancy P.

Book ID: 124139242
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 876 KB
Volume: 89
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2014.04.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 Study of Consolidative Involved-

Phase 2 Study of Consolidative Involved-Node Proton Therapy in Patients With Hodgkin Lymphoma: Early Outcomes

✍ Hoppe, B.S.; Flampouri, S.; Dang, N.H.; Lynch, J.W.; Morris, C.G.; Li, Z.; Mende 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Consolidative Involved-Node Proton Thera

Consolidative Involved-Node Proton Therapy for Stage IA-IIIB Mediastinal Hodgkin Lymphoma: Preliminary Dosimetric Outcomes From a Phase II Study

✍ Bradford S. Hoppe; Stella Flampouri; Zhong Su; Christopher G. Morris; Naeem Lati 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 565 KB

Reduction of the treated volume to invol

Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin’s lymphoma

✍ Verhappen, Marieke H.; Poortmans, Philip M.P.; Raaijmakers, Esther; Raemaekers, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 562 KB

Mature Results of a Phase II Study of Ri

Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

✍ Advani, R. H.; Horning, S. J.; Hoppe, R. T.; Daadi, S.; Allen, J.; Natkunam, Y.; 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 154 KB

314Preliminary results of a phase II stu

314Preliminary results of a phase II study of combined modality therapy in primary CNS lymphoma. Trans-Tasman radiation oncology group

✍ O'Brien, P.; Roos, D.; Liew, K.-H.; Trotter, G.; Barton, M.; Walker, Q.; Poulsen 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Durable complete responses from therapy

Durable complete responses from therapy with combined epratuzumab and rituximab : Final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma

✍ John P. Leonard; Stephen J. Schuster; Christos Emmanouilides; Felix Couture; Nic 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

## Abstract ## BACKGROUND. In this international, multicenter trial, the authors evaluated rituximab (anti‐CD20) plus epratuzumab (anti‐CD22) in patients with postchemotherapy relapsed/refractory, indolent non‐Hodgkin lymphoma (NHL), including long‐term efficacy. ## METHODS. Forty‐nine patients